1. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
- Author
-
Bruno Martino, Daniele Cattaneo, Florian H. Heidel, Elisabetta Abruzzese, Gianni Binotto, Rossella Stella, Giulia Benevolo, Michele Cavo, Micaela Bergamaschi, Roberto Latagliata, Francesco Cavazzini, Novella Pugliese, Massimo Breccia, Alessandro Isidori, Gianpietro Semenzato, Daniela Bartoletti, Mauro Krampera, Malgorzata Monica Trawinska, Costanza Bosi, Giovanni Caocci, Fabrizio Pane, Alessia Tieghi, Francesca Palandri, Roberto M. Lemoli, Elena Maria Elli, Antonio Cuneo, Fiorella Ciantia, Alessandra Iurlo, Monica Crugnola, Giuseppe Auteri, Mario Tiribelli, Massimiliano Bonifacio, Nicola Vianelli, Luigi Scaffidi, Giuseppe A. Palumbo, Nicola Polverelli, Palandri F., Palumbo G.A., Elli E.M., Polverelli N., Benevolo G., Martino B., Abruzzese E., Tiribelli M., Tieghi A., Latagliata R., Cavazzini F., Bergamaschi M., Binotto G., Crugnola M., Isidori A., Caocci G., Heidel F., Pugliese N., Bosi C., Bartoletti D., Auteri G., Cattaneo D., Scaffidi L., Trawinska M.M., Stella R., Ciantia F., Pane F., Cuneo A., Krampera M., Semenzato G., Lemoli R.M., Iurlo A., Vianelli N., Cavo M., Breccia M., and Bonifacio M.
- Subjects
Ruxolitinib ,medicine.medical_specialty ,Humans ,Janus Kinases ,Multivariate Analysis ,Primary Myelofibrosis ,Protein Kinase Inhibitors ,Pyrazoles ,Risk Factors ,Treatment Outcome ,medicine.medical_treatment ,Splenectomy ,lcsh:RC254-282 ,Nitriles ,Pyrimidines ,Ruxolitinib discontinuation syndrome, risk factors, myelofibrosis ,NO ,Myeloproliferative disease ,Internal medicine ,Correspondence ,medicine ,Risk factor ,Bone pain ,Myelofibrosis ,Respiratory distress ,business.industry ,Incidence (epidemiology) ,Hematology ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Discontinuation ,Oncology ,medicine.symptom ,business ,Haematological diseases ,medicine.drug - Abstract
No abstract available
- Published
- 2020